The property sector is seeing an influx of local and international capacity.
Australia’s insurance market is entering a softening phase as competition increases, particularly in property and financial lines, according to WTW’s latest Global…
SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London.
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your Jefferies representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar’s pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer, in several ongoing clinical trials.
Nektar is headquartered in San Francisco, California. For further information, visit http://www.nektar.com and follow us on LinkedIn.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
Jonathan Pappas
LifeSci Communications
857-205-4403
[email protected]
SOURCE Nektar Therapeutics
Prince Andrew will soon simply be known as Andrew Mountbatten Windsor after the process to strip the disgraced brother of King Charles III of all of his royal titles began today, but his daughters will keep theirs.
The formal process to remove…
King Charles has begun the formal process of stripping Prince Andrew of his title and forcing him to move out of his home in Windsor, in the latest embarrassing turn of events for Andrew and his family.
Buckingham Palace said Andrew, who was…
Samsung finally launched its Galaxy XR headset this month, so now everyone wants to know: What’s the battery life like?
While Mashable has yet to perform nuanced battery testing of our own, we at…
In a major scientific breakthrough, researchers have created the first comprehensive genetic resource to identify people at risk of dangerously high cholesterol and heart disease, even if their cholesterol levels appear normal. The…
Individuals diagnosed with
In our study, significant improvements were observed in emotional, social, and school-related domains of HRQOL among the cases, whereas physical functionality remained unchanged. The HRQOL quality of life scale can be used to evaluate the effects…
Researchers at the University of Chicago have developed a comprehensive mathematical model that predicts diabetes complications up to 15 years in advance, offering clinicians a powerful new tool to understand how early treatment decisions shape…